Latest & greatest articles for aids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for aids

501. Cost-effectiveness of an HIV/AIDS prevention intervention for gay men

Cost-effectiveness of an HIV/AIDS prevention intervention for gay men Cost-effectiveness of an HIV/AIDS prevention intervention for gay men Cost-effectiveness of an HIV/AIDS prevention intervention for gay men Holtgrave D R, Kelly J A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology An HIV/AIDS prevention intervention for gay men. Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population consisted of gay men who had engaged in behaviour with a high risk of HIV infection. Setting The setting was a medical school outreach programme. The economic study was carried out in the USA. Dates to which data relate Effectiveness data were collected from studies published

1997 NHS Economic Evaluation Database.

502. Assessment of computer-aided assistive technology: analysis of outcomes and costs

Assessment of computer-aided assistive technology: analysis of outcomes and costs Assessment of computer-aided assistive technology: analysis of outcomes and costs Assessment of computer-aided assistive technology: analysis of outcomes and costs Hass U, Andersson A, Brodin H, Persson J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Computer-Aided Assistive Technology (CAAT) for individuals with communication disabilities. Type of intervention Treatment and rehabilitation. Economic study type Cost-effectiveness analysis. Study population Male and female individuals with communication disabilities who were referred to the regional CAAT centres. Setting CAAT centres. The economic study was carried out in Uppsala, Sweden. Dates

1997 NHS Economic Evaluation Database.

503. Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis

Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis Freedberg K A, Cohen C J, Barber T W Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Prophylaxis for disseminated Mycobacterium avium Complex (MAC) infection in patients with AIDS: rifabutin (300 mg/day), azithromycin (1200mg/week) and clarithromycin (500 mg twice per day) were compared with no prophylaxis. Type of intervention Treatment; secondary

1997 NHS Economic Evaluation Database.

504. Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial. (PubMed)

Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial. 8634560 1996 07 05 1996 07 05 2013 11 21 0959-8138 312 7040 1996 May 11 BMJ (Clinical research ed.) BMJ Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial. 1187-91 To determine the value of short course, high dose albendazole chemotherapy in the treatment of persistent diarrhoea related (...) to HIV in unselected patients in urban Zambia. A randomised double blind placebo controlled trial of albendazole 800 mg twice daily for two weeks. Patients were monitored intensively for one month and followed for up to six months. Home care. AIDS services in Lusaka and Ndola. 174 HIV seropositive patients with persistent diarrhoea (defined as loose but not bloody stools three or more times a day for three weeks or longer). No investigations were undertaken except HIV testing after counselling

Full Text available with Trip Pro

1996 BMJ

505. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. (PubMed)

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. 8598838 1996 04 25 1996 04 25 2013 11 21 0028-4793 334 16 1996 Apr 18 The New England journal of medicine N. Engl. J. Med. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. 1011-7 In patients with human immunodeficiency virus (HIV) infection, combined treatment with several agents may increase

1996 NEJM

506. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. (PubMed)

Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. 8618603 1996 06 13 1996 06 13 2013 11 21 0028-4793 334 23 1996 Jun 06 The New England journal of medicine N. Engl. J. Med. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. 1491-7 In the advanced stages of the acquired immunodeficiency syndrome (AIDS), cytomegalovirus (CMV) disease (...) , particularly vision-damaging retinitis due to CMV is common. We evaluated prophylactic treatment with orally administered ganciclovir as a way to prevent CMV disease. We conducted a prospective, randomized, double-blind, placebo-controlled study of CMV infected persons with AIDS with either CD4+ lymphocyte counts of < or = 50 per cubic millimeter or counts of < or = 100 per cubic millimeter in those with a history of an AIDS defining opportunistic infection. Patients were randomly assigned, in a 2:1 ratio

1996 NEJM

507. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. (PubMed)

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. 8813038 1996 10 22 1996 10 22 2013 11 21 0028-4793 335 15 1996 Oct 10 The New England journal of medicine N. Engl. J. Med. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group (...) of zalcitabine; or 400 mg of didanosine. The primary end point was a > or = 50 percent decline in the CD4 cell count, development of the acquired immunodeficiency syndrome (AIDS), or death. Progression to the primary end point was more frequent with zidovudine alone (32 percent) than with zidovudine plus didanosine (18 percent; relative hazard ratio, 0.50; P<0.001), zidovudine plus zalcitabine (20 percent; relative hazard ratio, 0.54; P<0.001), or didanosine alone (22 percent; relative hazard ratio, 0.61; P

1996 NEJM

508. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. (PubMed)

The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. 8857005 1997 01 16 1997 01 16 2013 11 21 0028-4793 335 17 1996 Oct 24 The New England journal of medicine N. Engl. J. Med. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. 1261-9 Kaposi's sarcoma is the most common cancer in patients with the acquired immunodeficiency syndrome (AIDS). Recently, certain preparations of human chorionic gonadotropin (hCG) have (...) been shown to inhibit the growth of Kaposi's sarcoma cell lines in vitro and in immunodeficient mice. After in vitro evaluation of four commercially available hCG preparations, the most active product was evaluated in 36 patients with AIDS-related Kaposi's sarcoma. In a phase 1-2 trial, 24 patients received intralesional injections of hCG three times a week for two weeks at doses of 250, 500, 1000, or 2000 IU (6 patients each). In each patient three nodular lesions were injected, two with the drug

1996 NEJM

509. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. (PubMed)

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. 8813039 1996 10 22 1996 10 22 2013 11 21 0028-4793 335 15 1996 Oct 10 The New England journal of medicine N. Engl. J. Med. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per (...) cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. 1091-8 We studied measures of human immunodeficiency virus (HIV) replication, the viral phenotype, and immune function (CD4 cell counts) and the relation of changes in these indicators to clinical outcomes in a subgroup of patients in a controlled trial of early antiretroviral treatment for HIV, the AIDS Clinical Trials Group Study 175. The 391 subjects, each of whom entered the study with a single screening CD4 cell count

1996 NEJM

510. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. (PubMed)

A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. 8676931 1996 08 09 1996 08 09 2013 11 21 0028-4793 335 6 1996 Aug 08 The New England journal of medicine N. Engl. J. Med. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol (...) , and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. 377-83 Bacteremia with the Mycobacterium avium complex is common in patients with the acquired immunodeficiency syndrome (AIDS), but the most effective treatment for this infection remains unclear. We randomly assigned 229 patients with AIDS and M. avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram

1996 NEJM

511. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. (PubMed)

Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. 8965861 1996 12 06 1996 12 06 2013 11 21 0028-4793 335 22 1996 Nov 28 The New England journal of medicine N. Engl. J. Med. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol

1996 NEJM

512. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. (PubMed)

The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. 8943160 1996 12 13 1996 12 13 2015 11 19 0028-4793 335 24 1996 Dec 12 The New England journal of medicine N. Engl. J. Med. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. 1792-8 Transdermal nicotine therapy is widely used to aid smoking cessation, but there is uncertainty about its safety in patients with cardiac disease. In a randomized, double (...) -blind, placebo-controlled trial at 10 Veterans Affairs medical centers, we randomly assigned 584 outpatients (of whom 576 were men) with at least one diagnosis of cardiovascular disease to a 10-week course of transdermal nicotine or placebo as an aid to smoking cessation. The subjects were monitored for a total of 14 weeks for the primary end points of the study (death, myocardial infarction, cardiac arrest, and admission to the hospital due to increased severity of angina, arrhythmia, or congestive

1996 NEJM

513. The health effects of worksite HIV/AIDS interventions: a review of the research literature

The health effects of worksite HIV/AIDS interventions: a review of the research literature The health effects of worksite HIV/AIDS interventions: a review of the research literature The health effects of worksite HIV/AIDS interventions: a review of the research literature Wilson M G, Jorgensen C, Cole G Authors' objectives To examine the individual and organisational effects of HIV/AIDS interventions conducted in worksites. Searching The Centers for Disease Control and Prevention (CDCP (...) Information Service, and the Substance Abuse Information databases. Areas searched included HIV/AIDS, and multicomponent programmes. The CDC also manually searched health promotion journals to identify articles missed by the computer search, particularly those published after the search was conducted and those found in journals not included in the databases. The CDC search also checked references of identified articles for additional studies. In addition, the authors of this review manually searched new

1996 DARE.

514. Home care aides improve costs, outcomes, and satisfaction

Home care aides improve costs, outcomes, and satisfaction Home care aides improve costs, outcomes, and satisfaction Home care aides improve costs, outcomes, and satisfaction Swett E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health (...) technology Using home care aides (HCAs) in rehabilitation, supplementary to the physical, occupational, and speech home care therapy services. Type of intervention Rehabilitation. Economic study type Cost-effectiveness analysis. Study population Fracture patients requiring rehabilitation. Setting Community. The economic study was carried out in California, USA. Dates to which data relate The effectiveness and resource use data were collected in 1994 for the comparator and 1995 for the intervention

1996 NHS Economic Evaluation Database.

515. An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients

An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients Sullivan S D, Mozaffari E (...) , Johnson E S, Wolitz R, Follansbee S E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Pharmacologic agents (intravenous (IV) and oral ganciclovir) for treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. Type of

1996 NHS Economic Evaluation Database.

516. Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention

Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention Holtgrave D R, Kelly J A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) that generalisation of the results should be made only to organisations already delivering some type of "behaviourally based" HIV prevention programme (no capital or start-up costs were included). Source of funding Supported in part by grants RO1-MH55440 and P30-MH52776 from the National Institute of Mental Health. Bibliographic details Holtgrave D R, Kelly J A. Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention. American Journal of Public Health 1996; 86(10

1996 NHS Economic Evaluation Database.

517. Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients

Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients Freedberg K, Hardy D, Holzman R, Tosteson A, Craven D Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using trimethoprim-sulfamethoxazole (TMP-SMX) versus aerosolised pentamidine(AP) in the prevention of recurrent Pneumocystis carinii pneumonia (PCP) in AIDS patients with a previous PCP experience. Type

1996 NHS Economic Evaluation Database.

518. National AIDS programme managers, report on the eighth intercountry meeting, Amman, Jordan, 10-13 April 1995

National AIDS programme managers, report on the eighth intercountry meeting, Amman, Jordan, 10-13 April 1995 WHO IRIS: National AIDS programme managers, report on the eighth intercountry meeting, Amman, Jordan, 10-13 April 1995 Browse Related links Files in This Item: File Description Size Format 10.34 MB Adobe PDF Title: National AIDS programme managers, report on the eighth intercountry meeting, Amman, Jordan, 10-13 April 1995 Authors: Issue Date: 1995 Publisher: World Health Organization

1995 WHO

519. Report on the workshop on the role of media in AIDS prevention and control, Islamabad, Pakistan, 28-30 November 1994

Report on the workshop on the role of media in AIDS prevention and control, Islamabad, Pakistan, 28-30 November 1994 WHO IRIS: Report on the workshop on the role of media in AIDS prevention and control, Islamabad, Pakistan, 28-30 November 1994 Browse Related links Files in This Item: File Description Size Format 469.13 kB Adobe PDF Title: Report on the workshop on the role of media in AIDS prevention and control, Islamabad, Pakistan, 28-30 November 1994 Authors: Issue Date: 1995 Publisher

1995 WHO

520. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. (PubMed)

A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. 7616988 1995 08 24 1995 08 24 2013 11 21 0028-4793 333 7 1995 Aug 17 The New England journal of medicine N. Engl. J. Med. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. 401-7 (...) was modified so that open-label treatment with 500 mg of zidovudine per day (deferred therapy) was offered when CD4 cell counts fell below 500 per cubic millimeter. The study end points included overall survival, survival free of the acquired immunodeficiency syndrome (AIDS), toxic effects, and changes in CD4 cell counts. There were 1637 subjects who could be evaluated: 547 in the deferred-therapy group, 549 in the group receiving 500 mg of zidovudine immediately, and 541 in the 1500-mg group. The subjects

1995 NEJM